Page last updated: 2024-08-21

pyrazines and Soft Tissue Neoplasms

pyrazines has been researched along with Soft Tissue Neoplasms in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Antonescu, CR; Kraft, AS; Maki, RG; Scheu, K; Schwartz, GK; Wadler, S; Wright, JJ; Yamada, J	1
Booser, DJ; Broglio, KR; Cristofanilli, M; Esseltine, D; Gonzalez-Angulo, AM; Hortobagyi, GN; Islam, R; Krishnamurthy, S; Pusztai, L; Reuben, JM; Stec, J; Yang, CH	1
Bladé, J; Cibeira, MT; Laura, R; Montserrat, E; Salamero, O; Uriburu, C; Yantorno, S	1
Davidoff, AM; Dickson, PV; Hamner, JB; Ng, CY; Sims, TL; Spence, Y; Zhou, J	1

Trials

2 trial(s) available for pyrazines and Soft Tissue Neoplasms

Article	Year
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer, 2005, Apr-01, Volume: 103, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Drug Administration Schedule; Fatigue; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome	2005
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:5 Topics: Adult; Aged; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pleural Neoplasms; Protease Inhibitors; Pyrazines; Receptors, Estrogen; Receptors, Progesterone; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome	2006

Article

Year

A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.

Cancer, 2005, Apr-01, Volume: 103, Issue:7

Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Drug Administration Schedule; Fatigue; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome

2005

Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.

Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:5

Topics: Adult; Aged; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pleural Neoplasms; Protease Inhibitors; Pyrazines; Receptors, Estrogen; Receptors, Progesterone; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome

2006

Other Studies

2 other study(ies) available for pyrazines and Soft Tissue Neoplasms

Article	Year
Bortezomib: an effective agent in extramedullary disease in multiple myeloma. European journal of haematology, 2006, Volume: 76, Issue:5 Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Soft Tissue Neoplasms; Treatment Outcome	2006
Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma. Surgery, 2007, Volume: 142, Issue:2 Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; In Vitro Techniques; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Neuroblastoma; Pyrazines; Soft Tissue Neoplasms; Subcutaneous Tissue; Xenograft Model Antitumor Assays	2007

Article

Year

Bortezomib: an effective agent in extramedullary disease in multiple myeloma.

European journal of haematology, 2006, Volume: 76, Issue:5

Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Soft Tissue Neoplasms; Treatment Outcome

2006

Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma.

Surgery, 2007, Volume: 142, Issue:2

Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; In Vitro Techniques; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Neuroblastoma; Pyrazines; Soft Tissue Neoplasms; Subcutaneous Tissue; Xenograft Model Antitumor Assays

2007